LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac P… Read more
LifeTech Scientific Corporation (LFTSF) - Total Assets
Latest total assets as of June 2025: $5.33 Billion USD
Based on the latest financial reports, LifeTech Scientific Corporation (LFTSF) holds total assets worth $5.33 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LifeTech Scientific Corporation - Total Assets Trend (2010–2024)
This chart illustrates how LifeTech Scientific Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LifeTech Scientific Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
LifeTech Scientific Corporation's total assets of $5.33 Billion consist of 47.6% current assets and 52.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.6% |
| Accounts Receivable | $155.51 Million | 3.2% |
| Inventory | $532.40 Million | 10.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $730.66 Million | 14.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how LifeTech Scientific Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LifeTech Scientific Corporation's current assets represent 47.6% of total assets in 2024, a decrease from 83.0% in 2010.
- Cash Position: Cash and equivalents constituted 13.6% of total assets in 2024, down from 52.7% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 14.9% of total assets.
LifeTech Scientific Corporation Competitors by Total Assets
Key competitors of LifeTech Scientific Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
LifeTech Scientific Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LifeTech Scientific Corporation generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, LifeTech Scientific Corporation generates $ 4.54 in net profit.
LifeTech Scientific Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.59 | 2.68 | 1.32 |
| Quick Ratio | 2.09 | 2.02 | 1.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.58 Billion | $ 1.39 Billion | $ 153.69 Million |
LifeTech Scientific Corporation - Advanced Valuation Insights
This section examines the relationship between LifeTech Scientific Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $4.90 Billion |
| Market Capitalization | $838.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values LifeTech Scientific Corporation's assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: LifeTech Scientific Corporation's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for LifeTech Scientific Corporation (2010–2024)
The table below shows the annual total assets of LifeTech Scientific Corporation from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.90 Billion | +4.34% |
| 2023-12-31 | $4.70 Billion | +27.27% |
| 2022-12-31 | $3.69 Billion | +15.91% |
| 2021-12-31 | $3.18 Billion | +7.76% |
| 2020-12-31 | $2.95 Billion | +66.71% |
| 2019-12-31 | $1.77 Billion | +15.75% |
| 2018-12-31 | $1.53 Billion | +20.58% |
| 2017-12-31 | $1.27 Billion | -4.53% |
| 2016-12-31 | $1.33 Billion | +65.87% |
| 2015-12-31 | $801.89 Million | +41.60% |
| 2014-12-31 | $566.29 Million | +8.91% |
| 2013-12-31 | $519.98 Million | +42.79% |
| 2012-12-31 | $364.15 Million | +16.26% |
| 2011-12-31 | $313.22 Million | +97.67% |
| 2010-12-31 | $158.46 Million | -- |